Rajesh Nare, Vishal Dnyaneshwar Sawant, Rahul Surve
{"title":"极低出生体重(ELBW)和超低出生体重(VLBW)新生儿的代谢性骨病概况","authors":"Rajesh Nare, Vishal Dnyaneshwar Sawant, Rahul Surve","doi":"10.1186/s43054-024-00268-0","DOIUrl":null,"url":null,"abstract":"Metabolic bone disease (MBD) is an important cause of morbidity in premature, very low birth weight (VLBW), and sick infants and, if left undiagnosed, may lead to structural deformities and spontaneous fractures. The objective of the present study was to study the profile of MBD and to determine the incidence of MBD in infants ≤ 32 weeks/≤ 1250 g at birth. A total of 57 infants ≤ 32 weeks/≤ 1250 g at birth admitted in our NICU from October 2020 to July 2021 were included in the study. These infants underwent screening for MBD at 4 weeks of age. They were stratified into three groups based on their gestation (≤ 28 weeks, 29–30 weeks, 31–32 weeks). MBD was observed in 100% of extreme preterm babies and 69% of very preterm babies. Overall, the incidence of MBD was 73%. Serum phosphorus level normalized by 42–44 weeks post menstrual age (PMA) across all gestations. Alkaline phosphatase (ALP) levels normalized by 42–44 weeks only in very preterm babies. Seventeen babies ≤ 30 weeks required inorganic phosphorus supplementation in addition to calcium phosphate supplementation in order to correct the MBD. Drugs like caffeine, steroids, and furosemide have significant impact on the development of MBD. The time to reach full feeds with fortification had no statistically significant effect on the incidence of MBD as detected by serum phosphorus level and serum ALP level. The profile outlined in the present study matches the literature reports in many aspects, revealing the importance of characterizing this group for the prognosis and short- and long-term follow-up of newborns with bone metabolic disease.","PeriodicalId":43064,"journal":{"name":"Egyptian Pediatric Association Gazette","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Profile of metabolic bone disease in extremely low birth weight (ELBW) and very low birth weight (VLBW) neonates\",\"authors\":\"Rajesh Nare, Vishal Dnyaneshwar Sawant, Rahul Surve\",\"doi\":\"10.1186/s43054-024-00268-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Metabolic bone disease (MBD) is an important cause of morbidity in premature, very low birth weight (VLBW), and sick infants and, if left undiagnosed, may lead to structural deformities and spontaneous fractures. The objective of the present study was to study the profile of MBD and to determine the incidence of MBD in infants ≤ 32 weeks/≤ 1250 g at birth. A total of 57 infants ≤ 32 weeks/≤ 1250 g at birth admitted in our NICU from October 2020 to July 2021 were included in the study. These infants underwent screening for MBD at 4 weeks of age. They were stratified into three groups based on their gestation (≤ 28 weeks, 29–30 weeks, 31–32 weeks). MBD was observed in 100% of extreme preterm babies and 69% of very preterm babies. Overall, the incidence of MBD was 73%. Serum phosphorus level normalized by 42–44 weeks post menstrual age (PMA) across all gestations. Alkaline phosphatase (ALP) levels normalized by 42–44 weeks only in very preterm babies. Seventeen babies ≤ 30 weeks required inorganic phosphorus supplementation in addition to calcium phosphate supplementation in order to correct the MBD. Drugs like caffeine, steroids, and furosemide have significant impact on the development of MBD. The time to reach full feeds with fortification had no statistically significant effect on the incidence of MBD as detected by serum phosphorus level and serum ALP level. The profile outlined in the present study matches the literature reports in many aspects, revealing the importance of characterizing this group for the prognosis and short- and long-term follow-up of newborns with bone metabolic disease.\",\"PeriodicalId\":43064,\"journal\":{\"name\":\"Egyptian Pediatric Association Gazette\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2024-02-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Egyptian Pediatric Association Gazette\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s43054-024-00268-0\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Egyptian Pediatric Association Gazette","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43054-024-00268-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PEDIATRICS","Score":null,"Total":0}
Profile of metabolic bone disease in extremely low birth weight (ELBW) and very low birth weight (VLBW) neonates
Metabolic bone disease (MBD) is an important cause of morbidity in premature, very low birth weight (VLBW), and sick infants and, if left undiagnosed, may lead to structural deformities and spontaneous fractures. The objective of the present study was to study the profile of MBD and to determine the incidence of MBD in infants ≤ 32 weeks/≤ 1250 g at birth. A total of 57 infants ≤ 32 weeks/≤ 1250 g at birth admitted in our NICU from October 2020 to July 2021 were included in the study. These infants underwent screening for MBD at 4 weeks of age. They were stratified into three groups based on their gestation (≤ 28 weeks, 29–30 weeks, 31–32 weeks). MBD was observed in 100% of extreme preterm babies and 69% of very preterm babies. Overall, the incidence of MBD was 73%. Serum phosphorus level normalized by 42–44 weeks post menstrual age (PMA) across all gestations. Alkaline phosphatase (ALP) levels normalized by 42–44 weeks only in very preterm babies. Seventeen babies ≤ 30 weeks required inorganic phosphorus supplementation in addition to calcium phosphate supplementation in order to correct the MBD. Drugs like caffeine, steroids, and furosemide have significant impact on the development of MBD. The time to reach full feeds with fortification had no statistically significant effect on the incidence of MBD as detected by serum phosphorus level and serum ALP level. The profile outlined in the present study matches the literature reports in many aspects, revealing the importance of characterizing this group for the prognosis and short- and long-term follow-up of newborns with bone metabolic disease.
期刊介绍:
The Gazette is the official journal of the Egyptian Pediatric Association. The main purpose of the Gazette is to provide a place for the publication of high-quality papers documenting recent advances and new developments in both pediatrics and pediatric surgery in clinical and experimental settings. An equally important purpose of the Gazette is to publish local and regional issues related to children and child care. The Gazette welcomes original papers, review articles, case reports and short communications as well as short technical reports. Papers submitted to the Gazette are peer-reviewed by a large review board. The Gazette also offers CME quizzes, credits for which can be claimed from either the EPA website or the EPA headquarters. Fields of interest: all aspects of pediatrics, pediatric surgery, child health and child care. The Gazette complies with the Uniform Requirements for Manuscripts submitted to biomedical journals as recommended by the International Committee of Medical Journal Editors (ICMJE).